Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lacritin
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : $3.0 million
Deal Type : Series B Financing
TearSolutions Secures $3M Series B Funding
Details : The proceeds will accelerate company's programs for rare corneal diseases at preclinical and clinical stages, including Lacripep, derived from the Lacritin protein, a first-in-class topical therapy.
Product Name : Lacripep
Product Type : Peptide
Upfront Cash : Undisclosed
November 21, 2024
Lead Product(s) : Lacritin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : $3.0 million
Deal Type : Series B Financing
Lead Product(s) : Lacripep
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
July 21, 2017
Lead Product(s) : Lacripep
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
